In this study, we analyzed multiple somatic mutations in 10 genes relevant in melanoma tumorigenesis and targeted therapies. Overall, 45% of the tumors showed mutations and, in particular, 33% had multiple mutations. Based on our results, we conclude that the assessment of mutation status of multiple genes, including CDKN2A, could provide a genetic profile that can be useful as a prognostic and therapeutic marker in melanocytic tumors. © 2014 S. Karger AG, Basel
<div><h3>Purpose</h3><p>Knowledge of tumor mutation status is becoming increasingly important for th...
Diversity between metastatic melanoma tumours in individual patients is known; however, the molecula...
Cyclin-dependent kinase inhibitor type 2A (CDKN2A) has been identified as a major melanoma susceptib...
Introduction: Multiple primary melanomas (MPM) occur up to 8% of patients with cutaneous malignant m...
Background: Little is known about the prognostic significance of somatically mutated genes in metast...
Knowledge of tumor mutation status is becoming increasingly important for the treatment of cancer, a...
grantor: University of TorontoOnce a melanoma has reached the vertical growth phase the in...
Next generation sequencing (NGS) has been used to characterize the overall genomic landscape of mela...
Cyclin-dependent kinase inhibitor type 2A (CDKN2A) has been identified as a major melanoma susceptib...
Success with molecular-based targeted drugs in the treatment of cancer has ignited extensive researc...
Although germline mutations in CDKN2A are present in approximately 25% of large multicase melanoma f...
utaneous malignant melanoma (CMM; MIM#155601) comprises about 1 % of all cancer cases in European po...
To reveal the clonal architecture of melanoma and associated driver mutations, whole genome sequenci...
BACKGROUND: : Inherited mutations in the CDKN2A tumor suppressor gene, which encodes the p16(INK4a) ...
Cyclin-dependent kinase inhibitor type 2A (CDKN2A) has been identified as a major melanoma susceptib...
<div><h3>Purpose</h3><p>Knowledge of tumor mutation status is becoming increasingly important for th...
Diversity between metastatic melanoma tumours in individual patients is known; however, the molecula...
Cyclin-dependent kinase inhibitor type 2A (CDKN2A) has been identified as a major melanoma susceptib...
Introduction: Multiple primary melanomas (MPM) occur up to 8% of patients with cutaneous malignant m...
Background: Little is known about the prognostic significance of somatically mutated genes in metast...
Knowledge of tumor mutation status is becoming increasingly important for the treatment of cancer, a...
grantor: University of TorontoOnce a melanoma has reached the vertical growth phase the in...
Next generation sequencing (NGS) has been used to characterize the overall genomic landscape of mela...
Cyclin-dependent kinase inhibitor type 2A (CDKN2A) has been identified as a major melanoma susceptib...
Success with molecular-based targeted drugs in the treatment of cancer has ignited extensive researc...
Although germline mutations in CDKN2A are present in approximately 25% of large multicase melanoma f...
utaneous malignant melanoma (CMM; MIM#155601) comprises about 1 % of all cancer cases in European po...
To reveal the clonal architecture of melanoma and associated driver mutations, whole genome sequenci...
BACKGROUND: : Inherited mutations in the CDKN2A tumor suppressor gene, which encodes the p16(INK4a) ...
Cyclin-dependent kinase inhibitor type 2A (CDKN2A) has been identified as a major melanoma susceptib...
<div><h3>Purpose</h3><p>Knowledge of tumor mutation status is becoming increasingly important for th...
Diversity between metastatic melanoma tumours in individual patients is known; however, the molecula...
Cyclin-dependent kinase inhibitor type 2A (CDKN2A) has been identified as a major melanoma susceptib...